Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0828 ECP Concarlo
BioCentury & Getty Images

Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

SUNY Downstate spinout takes aim at metastatic breast cancer by targeting p27

By targeting p27, SUNY Downstate spinout Concarlo simultaneously takes aim at mechanisms of proliferation and resistance in cancer, starting with metastatic breast cancer. 

Aug 28, 2020 | 9:42 PM GMT

Concarlo is developing targeted therapies

Read the full 592 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers